Markets:

Overview

News

Currencies

International

Treasuries

Invesco Pharmaceuticals ETF (NY:PJP)

106.11 +0.38 (+0.36%)

Official Closing Price Updated: 4:10 PM EST, Jan 27, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Invesco Pharmaceuticals ETF

< Previous 1 2 Next >

Why Did OCUL Stock Jump 13% In Pre-Market Today? ↗

January 15, 2026

French pharmaceutical giant Sanofi is preparing an offer to acquire the American biopharmaceutical firm, according to a report by French publication La Lettre.

Via Stocktwits

US-UK Near Landmark Zero-Tariffs Pharma Deal, Announcement Expected Soon: Report ↗

December 01, 2025

The report states that the agreement between the U.S. and the U.K. is expected to be announced in the coming days.

Via Stocktwits

Topics World Trade

Eli Lilly CEO Slams PBM 'Rent Taking', Says They Drove Insulin List Prices To $275: 'We Can Disintermediate Them Easily' ↗

November 12, 2025

Eli Lilly CEO Dave Ricks slams PBM "rent taking" for driving $275 insulin price bubble and explains why he's ready to "disintermediate them."

Via Benzinga

Trump's 100% Drug Tariff Will Hit Americans, Economist Says Buyers 'Eat The Cost,' Not Foreign Firms ↗

September 29, 2025

President Donald Trump's proposed 100% tariffs on foreign pharmaceuticals will ultimately be paid by American patients and insurers, not foreign drug companies, according to economist Justin Wolfers.

Via Benzinga

Topics Government World Trade

Merck’s Blockbuster Drug Keytruda Gets Canadian Regulator’s Approval For Treating Cervical Cancer: Retail Investors Appear Divided ↗

July 21, 2025

Via Stocktwits

Mark Cuban Exposes How Wholesalers Force Pharmacies Into Near-Exclusive Deals, Detailing PBMs' 'Stranglehold' On Drug Pricing ↗

September 08, 2025

Mark Cuban explains how PBMs & wholesalers force pharmacies into exclusive deals, creating a 'stranglehold' on prescription drug prices.

Via Benzinga

Mark Cuban Says Cutting PBM Fees Won't Reduce Pharmaceutical R&D Funding: 'Manufacturers Can Sell To Us For More' ↗

August 01, 2025

Mark Cuban challenges the idea that high drug prices are necessary for R&D, PBMs take away from profits, leaving less for innovation.

Via Benzinga

Trump's Pharma Tariffs Can Hit Novo Nordisk, Says Barclays Expert, But It's 'Difficult' To Predict As Drugmakers Have 'Complex Supply Chains' ↗

July 16, 2025

Barclays has said that it's hard to predict which firm would be affected the most by pharma tariffs, except for Novo Nordisk.

Via Benzinga

Topics Government World Trade

FDA May Fast-Track New Drug Reviews In Return For Companies Lowering Drug Prices: Report ↗

July 11, 2025

FDA Commissioner Marty Makary floated the idea in an interview on Bloomberg Television.

Via Stocktwits

Topics Government

Trump Threatens 200% Pharma Tariffs, But Analyst Says This Stock Is Immune And Expected To 'Benefit' From Levies ↗

July 11, 2025

Donald Trump's proposed 200% tariffs can squeeze the profit margins of pharma companies, but LLY is poised to "benefit" except for the rest.

Via Benzinga

Topics Government World Trade

Mark Cuban Corrects Elizabeth Warren As She Slams JNJ, PFE For Higher Prices And Zero Taxes On Big Pharma: 'PBMs Corrupt Healthcare' ↗

June 20, 2025

A debate over the healthcare system erupted on X, pitting Mark Cuban against Elizabeth Warren over the root causes of soaring drug prices.

Via Benzinga

FDA Aims To Reduce Drug Application Review Time With New Voucher Program ↗

June 17, 2025

The FDA Commissioner will issue vouchers that drug developers may redeem to participate in a program that will shorten its review time from about 10-12 months to 1-2 months after the company’s final...

Via Stocktwits

Trump's Drug Price Order Hits PBMs Hardest: CVS, Cigna, UNH In Focus As Experts Highlight 'Racket,' Pricing Distortion ↗

May 19, 2025

Trump signed an executive order to lower drug prices, which could hit pharmacy benefit managers (PBMs) hard. PBMs have come under scrutiny for opaque pricing practices. Mark Cuban calls PBMs a racket.

Via Benzinga

Topics Government

Trump Says Prescription Drug Prices Set To Drop By 30% To 80% 'Almost Immediately' Thanks To 'Most Favored Nation' Plan, Mark Cuban Urges President To 'Force Transparency' ↗

May 11, 2025

Trump vows to slash drug prices with new executive order, potentially dropping them by 30-80%.

Via Benzinga

Topics Government

Sandoz CEO Richard Saynor Slams Proposal For Europe-Wide List Price For New Medicines, Says Report ↗

April 28, 2025

Saynor told Reuters that the proposal, put forth by Novartis and Sanofi in a letter to the Financial Times on Wednesday, overlooks the structural drivers of high drug prices in the United States and...

Via Stocktwits

Topics Government Intellectual Property Lawsuit

Trump Administration Considers Lowering US Drug Prices To International Levels: Report ↗

April 23, 2025

The Trump Administration is reportedly mulling over a policy to match U.S. drug prices with those in other developed nations.

Via Benzinga

Topics Government

Eli Lilly, AbbVie, Bristol Myers, Regeneron, And Other Pharma Companies Slide As Donald Trump Confirms Tariffs On Pharma Companies ↗

April 11, 2025

Even as Donald Trump paused the reciprocal tariffs for 90 days, he later confirmed that pharmaceutical companies would face tariffs.

Via Benzinga

Topics Government World Trade

FDA Commissioner Califf Candid on Trump's Impact: 'We Just Don't Know What's Going to Happen' ↗

November 13, 2024

FDA Chief Robert Califf reflects on potential changes as Trump's re-election looms, expressing disappointment and highlighting uncertainty within the agency.

Via Benzinga

Topics Government

FDA Set To Approve COVID-19 Vaccines As Soon As This Week: Stocks, ETFs To Watch ↗

August 19, 2024

The FDA may approve updated COVID-19 vaccines this week to combat recent strains as the country endures a significant summer outbreak.

Via Benzinga

Topics ETFs

COVID Activity Is Elevated Across 26 States In Summer Surge, Biden Remains In Isolation: 3 Vaccine Stocks To Watch ↗

July 18, 2024

Over half of US states have high levels of Covid-19 in wastewater as President Biden isolates with virus. New vaccines expected by Sept.

Via Benzinga

Purdue Pharma Bankruptcy Plan Rejected by Supreme Court, Billionaire Sacklers to Face Lawsuits ↗

June 27, 2024

The Supreme Court has rejected Purdue Pharma's bankruptcy plan, exposing the Sackler family to lawsuits over their role in the opioid crisis. This decision impacts victims, state and local governments,...

Via Benzinga

Topics Bankruptcy Lawsuit

A Look At Pharma ETFs Post Q1 Earnings ↗

May 07, 2024

Pharma ETFs have delivered mixed performances over the past month.

Via Talk Markets

Topics ETFs

A Look At Pharma ETFs After Q4 Earnings ↗

February 12, 2024

The fourth-quarter results of the healthcare sector have been unimpressive, with earnings of companies that have reported so far down 17.7% despite 7% revenue growth.

Via Talk Markets

Topics ETFs

Government-granted Patent Monopolies Are Not The Free Market ↗

December 29, 2023

Our system for developing new drugs is a disaster. While we can point to great successes, they come at enormous cost. We will spend over $600B this year on prescription and non-prescription drugs -...

Via Talk Markets

Topics Intellectual Property

Time For Gilead Sciences-Heavy ETFs? ↗

September 12, 2023

Gilead Sciences has underperformed the broader market this year by a hefty margin.

Via Talk Markets

Pharma ETFs in Focus Post Q2 Earnings ↗

August 11, 2023

Second-quarter earnings for the healthcare sector have been unimpressive, with earnings of companies that have reported so far down 30.7% on 5% revenue growth.

Via Talk Markets

Topics ETFs

Want to Invest in Pharmaceutical Stocks but Don't Know How? Try This ETF. ↗

May 18, 2023

Simplify your exposure to an ever-changing prescription drug market with this rules-based fund.

Via The Motley Fool

Pharma ETFs Gain Post Q1 Earnings ↗

May 09, 2023

Pharma ETFs have been in the green over the past month.

Via Talk Markets

A Look At Pharma ETFs Post Q4 Earnings ↗

February 08, 2023

Many industry bigwigs reported solid results, with some beating on earnings or revenues or both. However, solid earnings failed to fully impress pharma ETFs over the past month.

Via Talk Markets

Pharma ETFs In Focus Post Q3 Earnings ↗

November 09, 2022

Many industry bigwigs reported solid results with some beating on earnings or revenues or both. However, solid earnings failed to fully impress pharma ETFs over the past month.

Via Talk Markets

< Previous 1 2 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.